REQUEST A DEMO
Total
USD $0.00
Search more companies

Jaber Ebne Hayyan Pharmaceutical Company Public Joint Stock (Iran)

Main Activities: Medicinal and Botanical Manufacturing
Full name: Jaber Ebne Hayyan Pharmaceutical Company Public Joint Stock Profile Updated: March 13, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Jaber Ebne Hayyan Pharmaceutical Company Public Joint Stock, located in Tehran, is a pharmaceutical company that was established in 1339 A.H. Originally known as Squibb Iran, the company operated under the license of Squibb America and focused on producing cardiovascular, antitussive, and tonic corticosteroid drugs. Following the Iranian Islamic Revolution, multinational companies, including Squibb, were nationalized and brought under the National Industries Organization. As a result, the company was renamed Jaber Ebne Hayyan Pharmaceutical and became a public company in 1370. Currently, Jaber Ebne Hayyan Pharmaceutical Company is a leading producer of injectable and non-injectable antibiotics and respiratory sprays in Iran. The company's success in these areas is attributed to the expertise of its experienced professionals and the use of advanced devices in production.

Headquarters
Km 5 Karaj Special Road, P.O.Box: 13185-1739
Tehran; Tehran; Postal Code: 13988-34511

Contact Details: Purchase the Jaber Ebne Hayyan Pharmaceutical Company Public Joint Stock report to view the information.

Website: http://www.jaber-pharma.com

Basic Information
Total Employees:
Purchase the Jaber Ebne Hayyan Pharmaceutical Company Public Joint Stock report to view the information.
Outstanding Shares:
Purchase the Jaber Ebne Hayyan Pharmaceutical Company Public Joint Stock report to view the information.
Financial Auditors:
Purchase the Jaber Ebne Hayyan Pharmaceutical Company Public Joint Stock report to view the information.
Incorporation Date:
1961
Key Executives
Purchase this report to view the information.
Chairperson
Purchase this report to view the information.
Director / Member of the Management Board
Purchase this report to view the information.
Director / Member of the Management Board
Purchase this report to view the information.
Director / Member of the Management Board
Purchase this report to view the information.
Chief Executive Officer
Ownership Details
Purchase this report to view the information.
16.58%
Purchase this report to view the information.
1.15%
Purchase this report to view the information.
Subsidiaries
Ramopharmin Company Private Jo
Company Performance
Financial values in the chart are available after Jaber Ebne Hayyan Pharmaceutical Company Public Joint Stock report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency IRR. Absolute financial data is included in the purchased report.
Net sales revenue
89.3%
Total operating revenue
89.11%
Operating profit (EBIT)
-27.38%
Net Profit (Loss) for the Period
-27.49%
Total assets
52.17%
Total equity
11.35%
Operating Profit Margin (ROS)
-27.43%
Net Profit Margin
-20.15%
Return on Equity (ROE)
-11.02%
Debt to Equity Ratio
21.14%
Quick Ratio
-0.06%
Cash Ratio
0%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?